Recent Updates
Recently added Catalysts
SMMT Positive Sentiment

Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China

Sunday, September 13, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Summit Therapeutics' partner, Akeso Inc., has reported updated data from the Phase III HARMONi-2 trial, which demonstrates that ivonescimab monotherapy provides significant and clinically meaningful benefits compared to pembrolizumab in patients with PD-L1-positive advanced NSCLC. This data will be presented at the IASLC 2026 World Conference on Lung Cancer in Seoul.

Market Sentiment Analysis

POSITIVE FACTORS

  • Ivonescimab shows statistically significant benefits over pembrolizumab.
  • The trial results indicate a meaningful improvement in overall survival.
  • The study is being presented at a prestigious international conference.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+1236%
120-day peak, hindsight
Typical move
47.7%
average across 2 past catalysts
Cash runway
~13 mo
Low dilution risk
Lead asset
Ivonescimab
Phase 3 · Non-Small Cell Lung Cancer

Full Press Release Details

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. announced that updated data, including overall survival (OS), from the randomized, double-blind Phase III HARMONi-2 trial featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab is being presented at the International Association for the Study of Lung Cancer’s (IASLC) 2026 World Conference on Lung Cancer (WCLC 2026) in Seoul, Republic of Korea. The HARMON

Frequently Asked Questions

What is ivonescimab?

Ivonescimab is a novel bispecific antibody being investigated for treating advanced NSCLC.

What were the results of the HARMONi-2 trial?

The trial showed that ivonescimab significantly improves overall survival compared to pembrolizumab.

Where will the trial data be presented?

The data will be presented at the IASLC 2026 World Conference on Lung Cancer in Seoul.

What type of study was HARMONi-2?

HARMONi-2 was a randomized, double-blind Phase III clinical trial.

ShareAdd on Google
Tags: SMMT Viatris Investor Conferences Healthcare ivonescimab pembrolizumab NSCLC HARMONi-2
Last updated: Sep 13, 2026

Biotech snapshot

Cash runway
$691M liquidity · $47M/mo burn
~13 mo
Low dilution risk
Lead asset
IvonescimabPhase 3
Non-Small Cell Lung Cancer →

Catalyst track record

+1236%
best trade around SMMT's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for SMMT.

See every catalyst's timing & PoA →